ERBB2 and melanoma: Moreover, the ERBB2/ERBB3 complex seems to be a promising target for combination tumor therapy in cutaneous melanoma [44], and activated NOTCH1 and ERBB2/ERBB3 signaling are involved in melanoma pathogenesis [45], supporting our data.